Analysis of Artivion (NYSE: AORT) and PolyPid (NASDAQ: PYPD)

0

Artivion (NYSE:AORT – Get Rating) and PolyPid (NASDAQ:PYPD – Get Rating) are both small-cap medical companies, but which is the better investment? We’ll compare the two companies based on valuation strength, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Valuation and benefits

This table compares revenue, earnings per share (EPS), and valuation of Artivion and PolyPid.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Artivion $298.84 million 2.58 -$14.83 million ($0.39) -49.26
PolyPid N / A N / A -$42.60 million ($2.43) -1.87

Artivion has higher revenue and profit than PolyPid. Artivion trades at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Artivion has a beta of 1.49, which means its stock price is 49% more volatile than the S&P 500. In comparison, PolyPid has a beta of 0.78, which means its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares the net margins, return on equity and return on assets of Artivion and PolyPid.

Net margins Return on equity return on assets
Artivion -4.95% 3.08% 1.16%
PolyPid N / A -107.22% -93.58%

Analyst Notes

This is a summary of the current ratings and target prices for Artivion and PolyPid, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Artivion 0 0 2 0 3.00
PolyPid 0 0 2 1 3.33

Artivion currently has a consensus price target of $30.00, indicating a potential upside of 56.17%. PolyPid has a consensus price target of $18.67, indicating a potential upside of 311.16%. Given PolyPid’s stronger consensus rating and higher likely upside, analysts clearly think PolyPid is more favorable than Artivion.

Insider and Institutional Ownership

81.0% of Artivion shares are held by institutional investors. Comparatively, 20.8% of PolyPid shares are held by institutional investors. 5.6% of Artivion shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large money managers believe a company is poised for long-term growth.

Summary

Artivion beats PolyPid on 8 out of 13 factors compared between the two stocks.

Artivion Company Profile (Get an evaluation)

Artivion Inc. manufactures, processes and distributes medical devices and implantable human tissues worldwide. The Company offers BioGlue, a polymer composed of bovine blood proteins and a protein cross-linking agent for cardiac, vascular, neurological and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides engineered E-xtra design systems for the treatment of aortic vascular disease; E-nside, a ready-to-use stent for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent system for the minimally invasive repair of descending aortic lesions; E-ventus BX, a peripheral balloon-expandable stent graft for endovascular treatment of the renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysm stent system. Additionally, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powder hemostat for use in surgical procedures; cardiac laser therapy products for the treatment of angina pectoris; CryoVein Femoral Vein and CryoArtery Femoral Artery Vascular Preservation Services; On-X aortic and mitral heart valve prostheses and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral cord replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals and other healthcare facilities, as well as cardiac, vascular, thoracic and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

PolyPid Company Profile (Get an evaluation)

Polypid logoPolyPid Ltd., a late-stage biopharmaceutical company, develops, manufactures and markets products based on a polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.



Get news and reviews for Artivion Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Artivion and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

About Author

Comments are closed.